Skip to main content
Journal cover image

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Publication ,  Journal Article
Thompson, AJ; Muir, AJ; Sulkowski, MS; Ge, D; Fellay, J; Shianna, KV; Urban, T; Afdhal, NH; Jacobson, IM; Esteban, R; Poordad, F; Lawitz, EJ ...
Published in: Gastroenterology
July 2010

BACKGROUND & AIMS: We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic hepatitis C virus genotype 1 (HCV-1) infection. We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR. METHODS: HCV-1 patients were genotyped as CC, CT, or TT at the polymorphic site, rs12979860. Viral kinetics and rates of rapid virologic response (RVR, week 4), complete early virologic response (week 12), and SVR were compared by IL-28B type in 3 self-reported ethnic groups: Caucasians (n = 1171), African Americans (n = 300), and Hispanics (n = 116). RESULTS: In Caucasians, the CC IL-28B type was associated with improved early viral kinetics and greater likelihood of RVR (28% vs 5% and 5%; P < .0001), complete early virologic response (87% vs 38% and 28%; P < .0001), and SVR (69% vs 33% and 27%; P < .0001) compared with CT and TT. A similar association occurred within African Americans and Hispanics. In a multivariable regression model, CC IL-28B type was the strongest pretreatment predictor of SVR (odds ratio, 5.2; 95% confidence interval, 4.1-6.7). RVR was a strong predictor of SVR regardless of IL-28B type. In non-RVR patients, the CC IL-28B type was associated with a higher rate of SVR (Caucasians, 66% vs 31% and 24%; P < .0001). CONCLUSIONS: In treatment-naive HCV-1 patients treated with pegylated interferon and ribavirin, a polymorphism upstream of IL-28B is associated with increased on-treatment and sustained virologic response and effectively predicts treatment outcome.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gastroenterology

DOI

EISSN

1528-0012

Publication Date

July 2010

Volume

139

Issue

1

Start / End Page

120 / 9.e18

Location

United States

Related Subject Headings

  • Viral Load
  • Polymorphism, Single Nucleotide
  • Multivariate Analysis
  • Middle Aged
  • Male
  • Interleukins
  • Interferons
  • Humans
  • Hepatitis C
  • Hepacivirus
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Thompson, A. J., Muir, A. J., Sulkowski, M. S., Ge, D., Fellay, J., Shianna, K. V., … McHutchison, J. G. (2010). Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology, 139(1), 120-9.e18. https://doi.org/10.1053/j.gastro.2010.04.013
Thompson, Alexander J., Andrew J. Muir, Mark S. Sulkowski, Dongliang Ge, Jacques Fellay, Kevin V. Shianna, Thomas Urban, et al. “Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.Gastroenterology 139, no. 1 (July 2010): 120-9.e18. https://doi.org/10.1053/j.gastro.2010.04.013.
Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010 Jul;139(1):120-9.e18.
Thompson, Alexander J., et al. “Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.Gastroenterology, vol. 139, no. 1, July 2010, pp. 120-9.e18. Pubmed, doi:10.1053/j.gastro.2010.04.013.
Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010 Jul;139(1):120–9.e18.
Journal cover image

Published In

Gastroenterology

DOI

EISSN

1528-0012

Publication Date

July 2010

Volume

139

Issue

1

Start / End Page

120 / 9.e18

Location

United States

Related Subject Headings

  • Viral Load
  • Polymorphism, Single Nucleotide
  • Multivariate Analysis
  • Middle Aged
  • Male
  • Interleukins
  • Interferons
  • Humans
  • Hepatitis C
  • Hepacivirus